Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLTNASDAQ:CABANASDAQ:GLYCNASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.60+22.8%$0.43$0.30▼$10.62$85.36M23.28 million shs7.69 million shsCABACabaletta Bio$2.03+12.2%$1.37$0.99▼$13.50$103.01M2.721.54 million shs15.81 million shsGLYCGlycoMimetics$0.25-1.1%$0.24$0.14▼$0.63$15.94M1.76.51 million shs173,587 shsMDCXMedicus Pharma$6.73+13.1%$3.94$1.80▼$7.00$90.38MN/A65,954 shs310,901 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%+50.84%+81.05%-6.82%-86.30%CABACabaletta Bio0.00%+72.03%+84.55%-25.09%-84.00%GLYCGlycoMimetics0.00%+2.83%+10.76%-14.83%-8.52%MDCXMedicus Pharma0.00%+46.62%+68.25%+82.88%+672,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.0137 of 5 stars3.32.00.04.72.22.50.6CABACabaletta Bio2.3264 of 5 stars4.51.00.00.02.30.00.6GLYCGlycoMimetics2.1453 of 5 stars0.05.00.04.62.61.70.0MDCXMedicus PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.10911.78% UpsideCABACabaletta Bio 3.00Buy$20.33901.64% UpsideGLYCGlycoMimetics 2.33HoldN/AN/AMDCXMedicus Pharma 3.50Strong Buy$23.50249.18% UpsideCurrent Analyst Ratings BreakdownLatest GLYC, APLT, CABA, and MDCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CABACabaletta BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $13.005/15/2025CABACabaletta BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.005/14/2025APLTApplied TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.505/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/14/2025MDCXMedicus PharmaD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/14/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/1/2025CABACabaletta BioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $3.004/1/2025CABACabaletta BioUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $7.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$455K187.60N/AN/A($0.20) per share-3.01CABACabaletta BioN/AN/AN/AN/A$5.51 per shareN/AGLYCGlycoMimetics$10K1,593.94N/AN/A$0.08 per share3.09MDCXMedicus PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$119.76M-$0.43N/AN/AN/AN/A-260.75%-76.04%N/ACABACabaletta Bio-$67.68M-$2.34N/AN/AN/AN/A-50.10%-45.49%5/21/2025 (Estimated)GLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%N/AMDCXMedicus PharmaN/AN/A0.00N/AN/AN/AN/AN/A6/27/2025 (Estimated)Latest GLYC, APLT, CABA, and MDCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CABACabaletta Bio-$0.67-$0.71-$0.04-$0.71N/AN/A5/14/2025Q1 2025GLYCGlycoMimetics-$0.05-$0.04+$0.01-$0.04N/AN/A5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A4/14/2025Q4 2024APLTApplied Therapeutics-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million3/31/2025Q4 2024CABACabaletta Bio-$0.65-$0.65N/A-$0.65N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.061.06CABACabaletta BioN/A8.118.11GLYCGlycoMimeticsN/A1.921.92MDCXMedicus PharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%CABACabaletta BioN/AGLYCGlycoMimetics75.19%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics8.60%CABACabaletta Bio9.88%GLYCGlycoMimetics8.70%MDCXMedicus PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30141.58 million106.35 millionOptionableCABACabaletta Bio5050.74 million44.05 millionOptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionableMDCXMedicus PharmaN/A13.43 millionN/AN/AGLYC, APLT, CABA, and MDCX HeadlinesRecent News About These CompaniesMedicus Pharma (NASDAQ:MDCX) Announces Earnings Results, Misses Estimates By $0.19 EPSMay 14, 2025 | marketbeat.comD. Boral Capital Boosts Medicus Pharma (NASDAQ:MDCX) Price Target to $27.00May 14, 2025 | marketbeat.comMedicus Pharma LtdMay 14, 2025 | cnn.comMedicus Pharma (NASDAQ:MDCX) Price Target Raised to $27.00May 14, 2025 | americanbankingnews.comMedicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial PortfolioMay 12, 2025 | benzinga.comMedicus Pharma Ltd. plans strategic acquisitionMay 10, 2025 | pottsmerc.comMedicus Pharma to acquire Antev in strategic biotech dealApril 30, 2025 | uk.investing.comMedicus Pharma (NASDAQ:MDCX) Earns "Buy" Rating from D. Boral CapitalApril 30, 2025 | marketbeat.comMedicus Pharma signs letter of intent to buy British biotech companyApril 29, 2025 | bizjournals.comMedicus Pharma Ltd (MDCX)April 29, 2025 | investing.comMedicus to buy Antev for $75 millionApril 29, 2025 | thepharmaletter.comMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange TransactionApril 28, 2025 | finance.yahoo.comMedicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatmentApril 28, 2025 | proactiveinvestors.comMedicus Pharma to Acquire Antev Ltd. in $75 Million DealApril 28, 2025 | tipranks.comMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.April 28, 2025 | newsfilecorp.comMedicus Pharma (NASDAQ:MDCX) Receives "Buy" Rating from D. Boral CapitalApril 23, 2025 | marketbeat.comMedicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma TreatmentApril 21, 2025 | tipranks.comMedicus Pharma expands basal cell carcinoma study after encouraging early dataApril 21, 2025 | proactiveinvestors.comMedicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)April 21, 2025 | newsfilecorp.comD. Boral Capital Initiates Coverage of Medicus Pharma (MDCX) with Buy RecommendationApril 14, 2025 | msn.comValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks OutMarch 28, 2025 | wral.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLYC, APLT, CABA, and MDCX Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.60 +0.11 (+22.82%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.60 0.00 (-0.81%) As of 05/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Cabaletta Bio NASDAQ:CABA$2.03 +0.22 (+12.15%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$2.00 -0.03 (-1.67%) As of 05/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.GlycoMimetics NASDAQ:GLYC$0.25 0.00 (-1.12%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.25 0.00 (0.00%) As of 05/16/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Medicus Pharma NASDAQ:MDCX$6.73 +0.78 (+13.11%) As of 05/16/2025 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
